{"hands_on_practices": [{"introduction": "The ultimate biological impact of a chromosomal translocation often depends on whether it creates a novel, functional protein. This exercise provides a hands-on opportunity to apply fundamental principles of molecular biology to predict the functional consequences of a hypothetical gene fusion. By mapping genomic breakpoints to transcript coordinates and analyzing the reading frame, you will develop the critical skill of determining whether a fusion event is likely to be oncogenic or simply result in a non-functional, truncated product [@problem_id:5099386].", "problem": "A fusion transcript is detected by high-throughput sequencing of a hematologic malignancy. The structural variant joins the $5'$ portion of gene FUS5 (a coiled-coil oligomerization protein) to the $3'$ portion of gene KIN9 (a receptor tyrosine kinase), creating a FUS5–KIN9 chimera. The canonical protein-coding transcript of FUS5, designated $T_5$, initiates translation at exon $E2$. The canonical protein-coding transcript of KIN9, designated $T_9$, initiates translation at exon $E1$. The following coding sequence architecture is known and is applicable to the dominant transcripts in this tumor:\n\n- FUS5 $T_5$ coding exon spans and lengths (coding sequence numbering c.$1$ is the first coding base of $T_5$):\n  - $E2$: c.$1$–c.$180$ ($180$ base pairs)\n  - $E3$: c.$181$–c.$270$ ($90$ base pairs)\n  - $E4$: c.$271$–c.$480$ ($210$ base pairs)\n  - $E5$: c.$481$–c.$600$ ($120$ base pairs)\n  The FUS5 coiled-coil domain is encoded by c.$1$–c.$270$ (amino acids $1$–$90$).\n\n- KIN9 $T_9$ coding exon spans and lengths (coding sequence numbering c.$1$ is the first coding base of $T_9$):\n  - $E1$: c.$1$–c.$120$ ($120$ base pairs)\n  - $E2$: c.$121$–c.$270$ ($150$ base pairs)\n  - $E3$: c.$271$–c.$480$ ($210$ base pairs)\n  - $E4$: c.$481$–c.$660$ ($180$ base pairs)\n  - $E5$: c.$661$–c.$840$ ($180$ base pairs)\n  - $E6$: c.$841$–c.$1005$ ($165$ base pairs)\n  - $E7$: c.$1006$–c.$1125$ ($120$ base pairs)\n  - $E8$: c.$1126$–c.$1335$ ($210$ base pairs)\n  - $E9$: c.$1336$–c.$1515$ ($180$ base pairs)\n  - $E10$: c.$1516$–c.$1605$ ($90$ base pairs)\n  - $E11$: c.$1606$–c.$1815$ ($210$ base pairs)\n  - $E12$: c.$1816$–c.$1965$ ($150$ base pairs)\n  The KIN9 kinase domain is encoded by c.$810$–c.$1860$ (amino acids $270$–$620$).\n\nBreakpoints (at single-nucleotide resolution on the coding sequence coordinates of each transcript) are as follows:\n- FUS5 $T_5$ breakpoint occurs after c.$245$ (i.e., between c.$245$ and c.$246$).\n- KIN9 $T_9$ breakpoint occurs after c.$1005$ (i.e., between c.$1005$ and c.$1006$).\n\nThe fusion transcript is therefore: FUS5 c.$1$–c.$245$ joined to KIN9 c.$1006$–c.$1965$, driven by the FUS5 promoter and initiating translation from the FUS5 start codon. Fluorescence In Situ Hybridization (FISH) and Immunohistochemistry (IHC) corroborate the structural event, and a phospho-specific antibody recognizing the KIN9 activation loop epitope is available for functional assessment.\n\nUsing only foundational biological principles, including the Central Dogma of Molecular Biology (DNA to RNA to protein), the definition that translation proceeds in codons of length $3$ nucleotides, and the mapping of coding sequence to exons, determine the exon mapping at each breakpoint, whether the fusion is in-frame or out-of-frame at the junction, and predict the most likely effect on KIN9 protein function and the expected result of phospho-KIN9 IHC.\n\nWhich of the following is the most accurate interpretation?\n\nA. The FUS5 breakpoint lies in exon $E3$ and the KIN9 breakpoint lies at the end of exon $E6$; the fusion is out-of-frame at the junction, leading to a premature termination codon upstream of the KIN9 kinase domain, loss of kinase activity, likely nonsense-mediated decay, and negative phospho-KIN9 IHC.\n\nB. The FUS5 breakpoint lies in exon $E3$ and the KIN9 breakpoint lies at the end of exon $E6$; the fusion is in-frame, preserving the full KIN9 kinase domain downstream of the FUS5 coiled-coil, causing constitutive kinase activation and positive phospho-KIN9 IHC.\n\nC. The FUS5 breakpoint lies in exon $E2$ and the KIN9 breakpoint lies in exon $E7$; the fusion is in-frame and retains the entire kinase domain, predicting constitutive activation and positive phospho-KIN9 IHC.\n\nD. The FUS5 breakpoint lies in exon $E3$ and the KIN9 breakpoint lies at the end of exon $E6$; the fusion is out-of-frame but translation reinitiates at a downstream AUG within KIN9 to produce a near-full-length kinase, predicting positive phospho-KIN9 IHC.", "solution": "The user-provided problem statement is subjected to validation prior to any attempt at a solution.\n\n### Step 1: Extraction of Givens\n\n-   **Genes and Proteins**: Fusion of gene $FUS5$ (coiled-coil oligomerization protein) and gene $KIN9$ (receptor tyrosine kinase).\n-   **Transcripts**: Canonical transcript for $FUS5$ is $T_5$; for $KIN9$ is $T_9$.\n-   **Translation Initiation**: $T_5$ initiates translation at exon $E2$. $T_9$ initiates translation at exon $E1$.\n-   **$FUS5$ $T_5$ Coding Sequence (CDS) Architecture**:\n    -   $E2$: c.$1$–c.$180$ ($180$ bp)\n    -   $E3$: c.$181$–c.$270$ ($90$ bp)\n    -   $E4$: c.$271$–c.$480$ ($210$ bp)\n    -   $E5$: c.$481$–c.$600$ ($120$ bp)\n    -   Coiled-coil domain: encoded by c.$1$–c.$270$.\n-   **$KIN9$ $T_9$ Coding Sequence (CDS) Architecture**:\n    -   $E1$: c.$1$–c.$120$ ($120$ bp)\n    -   $E2$: c.$121$–c.$270$ ($150$ bp)\n    -   $E3$: c.$271$–c.$480$ ($210$ bp)\n    -   $E4$: c.$481$–c.$660$ ($180$ bp)\n    -   $E5$: c.$661$–c.$840$ ($180$ bp)\n    -   $E6$: c.$841$–c.$1005$ ($165$ bp)\n    -   $E7$: c.$1006$–c.$1125$ ($120$ bp)\n    -   $E8$: c.$1126$–c.$1335$ ($210$ bp)\n    -   $E9$: c.$1336$–c.$1515$ ($180$ bp)\n    -   $E10$: c.$1516$–c.$1605$ ($90$ bp)\n    -   $E11$: c.$1606$–c.$1815$ ($210$ bp)\n    -   $E12$: c.$1816$–c.$1965$ ($150$ bp)\n    -   Kinase domain: encoded by c.$810$–c.$1860$.\n-   **Breakpoints**:\n    -   $FUS5$ $T_5$: after c.$245$.\n    -   $KIN9$ $T_9$: after c.$1005$.\n-   **Fusion Transcript Structure**: $FUS5$ c.$1$–c.$245$ is joined to $KIN9$ c.$1006$–c.$1965$. Translation initiates from the $FUS5$ start codon.\n-   **Question**: Determine the exon mapping of the breakpoints, the reading frame status of the fusion, and predict the functional consequences for KIN9 protein and phospho-KIN9 Immunohistochemistry (IHC).\n\n### Step 2: Validation of Problem Statement\n\nThe problem statement is scientifically grounded, employing standard concepts and terminology from molecular biology, genetics, and oncology. The data provided, including gene structures, coding sequence coordinates, and exon boundaries, are internally consistent, with one minor exception. The KIN9 kinase domain is stated to be encoded by c.$810$–c.$1860$, which is a sequence of length $1860 - 810 + 1 = 1051$ nucleotides. This is not divisible by $3$, which contradicts the principle that protein-coding regions must have a length that is a multiple of $3$. However, all other numerical data, including all exon lengths and boundaries, are fully consistent. This minor inconsistency in the domain definition does not affect the central calculations regarding the fusion junction, which is the core of the problem. The problem is well-posed, objective, and provides all necessary information to derive a unique solution based on foundational principles.\n\n### Step 3: Verdict and Action\n\nThe problem is deemed **valid**. The minor inconsistency is noted but does not preclude a rigorous solution to the primary questions asked. Proceeding to solution derivation.\n\n### Derivation of the Correct Answer\n\nThe problem requires a three-part analysis: (1) mapping the breakpoints to their respective exons, (2) determining if the fusion is in-frame or out-of-frame, and (3) predicting the biological consequences.\n\n1.  **Exon Mapping of Breakpoints**\n    -   **$FUS5$ Breakpoint**: The break occurs after coding nucleotide c.$245$ of $FUS5$. The coding exons for $FUS5$ are given as $E2$: c.$1$–c.$180$ and $E3$: c.$181$–c.$270$. Since the position $245$ falls within the range $[181, 270]$, the $FUS5$ breakpoint is located within exon $E3$.\n    -   **$KIN9$ Breakpoint**: The break occurs after coding nucleotide c.$1005$ of $KIN9$. The coding exons for $KIN9$ around this position are $E6$: c.$841$–c.$1005$ and $E7$: c.$1006$–c.$1125$. The break is exactly at the boundary between exon $E6$ and exon $E7$. The fusion transcript contains the $KIN9$ sequence starting from c.$1006$, which corresponds to the beginning of exon $E7$. Therefore, the breakpoint can be described as occurring at the end of exon $E6$.\n\n2.  **Reading Frame Analysis**\n    -   The reading frame of a fusion protein is determined by the number of nucleotides contributed by the $5'$ partner gene, in this case $FUS5$. The fusion protein will be translated in the correct reading frame of the $3'$ partner gene ($KIN9$) only if the number of nucleotides from the $5'$ partner is a multiple of $3$.\n    -   The $FUS5$ gene contributes nucleotides c.$1$ through c.$245$, for a total of $245$ nucleotides.\n    -   To check if this maintains the reading frame, we calculate the remainder of $245$ when divided by $3$:\n    $$245 \\pmod 3 = (243 + 2) \\pmod 3 = 2$$\n    -   A remainder of $0$ is required to maintain the reading frame. Since the remainder is $2$, the junction is **out-of-frame**. The first nucleotide from $KIN9$ (c.$1006$) will be read as the third base of a codon, causing a frameshift. The protein sequence translated from the $KIN9$ portion of the transcript will be completely different from the canonical KIN9 amino acid sequence.\n\n3.  **Prediction of Biological Consequences**\n    -   An out-of-frame fusion results in the translation of a nonsense amino acid sequence downstream of the fusion junction.\n    -   This aberrant translation will almost certainly encounter a premature termination codon (PTC) in the new reading frame. The probability of a random codon being a stop codon is approximately $3/64$, meaning a PTC is expected to occur within a short distance (on average, $\\approx 21$ codons) from the junction.\n    -   The resulting protein will be truncated. It will consist of the first $81$ amino acids of $FUS5$ plus a few gibberish amino acids before translation terminates. Crucially, a functional KIN9 kinase domain will not be produced. This leads to a loss of the kinase activity associated with the fusion product.\n    -   Furthermore, messenger RNA transcripts containing PTCs are typically recognized and degraded by the cellular surveillance mechanism known as nonsense-mediated decay (NMD). This would further reduce or eliminate the production of the truncated protein.\n    -   The question asks about the result of phospho-KIN9 IHC. This assay uses an antibody that recognizes a phosphorylated epitope in the KIN9 activation loop, which is a critical part of the kinase domain. Since no functional kinase domain is translated from the fusion transcript, there will be no KIN9 activation loop to be phosphorylated. Therefore, the phospho-KIN9 IHC is expected to be **negative**.\n\n### Evaluation of Options\n\n-   **Option A**: \"The FUS5 breakpoint lies in exon $E3$ and the KIN9 breakpoint lies at the end of exon $E6$; the fusion is out-of-frame at the junction, leading to a premature termination codon upstream of the KIN9 kinase domain, loss of kinase activity, likely nonsense-mediated decay, and negative phospho-KIN9 IHC.\"\n    -   Exon mapping: Correct ($FUS5$ in $E3$, $KIN9$ at end of $E6$).\n    -   Frame status: Correct (out-of-frame).\n    -   Consequence prediction: Correct. A PTC will occur, leading to loss of kinase activity, likely NMD, and negative phospho-KIN9 IHC. The phrasing \"upstream of the KIN9 kinase domain\" is slightly imprecise, as the junction at c.$1006$ is *within* the sequence that normally encodes the kinase domain (c.$810$–c.$1860$). However, the PTC effectively arises before any functional domain can be formed. Among the given choices, this small inaccuracy does not invalidate the overall correctness of the statement.\n    -   **Verdict: Correct.**\n\n-   **Option B**: \"The FUS5 breakpoint lies in exon $E3$ and the KIN9 breakpoint lies at the end of exon $E6$; the fusion is in-frame, preserving the full KIN9 kinase domain downstream of the FUS5 coiled-coil, causing constitutive kinase activation and positive phospho-KIN9 IHC.\"\n    -   Frame status: Incorrect. The fusion is out-of-frame. All subsequent conclusions are therefore invalid.\n    -   **Verdict: Incorrect.**\n\n-   **Option C**: \"The FUS5 breakpoint lies in exon $E2$ and the KIN9 breakpoint lies in exon $E7$; the fusion is in-frame and retains the entire kinase domain, predicting constitutive activation and positive phospho-KIN9 IHC.\"\n    -   Exon mapping: Incorrect. The FUS5 breakpoint is in $E3$, not $E2$.\n    -   **Verdict: Incorrect.**\n\n-   **Option D**: \"The FUS5 breakpoint lies in exon $E3$ and the KIN9 breakpoint lies at the end of exon $E6$; the fusion is out-of-frame but translation reinitiates at a downstream AUG within KIN9 to produce a near-full-length kinase, predicting positive phospho-KIN9 IHC.\"\n    -   Frame status: Correct (out-of-frame).\n    -   Proposed mechanism: Translational reinitiation is a possible but inefficient and context-dependent mechanism in eukaryotes. It is not the primary or most predictable outcome of a frameshift. The most fundamental and common consequence is termination at a PTC and likely NMD, as described in Option A. This option is speculative and less probable than Option A.\n    -   **Verdict: Incorrect.**\n\nBased on a rigorous application of molecular biology principles, Option A provides the most accurate and comprehensive interpretation of the data.", "answer": "$$\\boxed{A}$$", "id": "5099386"}, {"introduction": "Reverse Transcription Quantitative Polymerase Chain Reaction (RT-qPCR) remains a cornerstone for the sensitive detection and monitoring of known fusion transcripts like BCR-ABL1. This practice challenges you to move beyond simply using an assay to understanding its quantitative limits from first principles. You will derive the analytical limit of detection (LOD) for an RT-qPCR assay by connecting the exponential nature of PCR amplification to the parameters of a standard curve, a crucial exercise for validating and interpreting clinical diagnostic tests [@problem_id:5099375].", "problem": "A laboratory assay is being developed to detect the BCR-ABL1 fusion transcript that results from the t$(9;22)$ chromosomal translocation (Philadelphia chromosome) using Reverse Transcription Quantitative Polymerase Chain Reaction (RT-qPCR). The assay uses a hydrolysis probe targeting the fusion junction, and a synthetic RNA standard curve spanning $6$ orders of magnitude in input template copies per reaction, from $10^{6}$ down to $10^{0}$ copies per reaction. The validated standard curve has a slope of $-3.6$ across this dynamic range, and the measured amplification efficiency is $0.90$. The cycle threshold (denoted $C_{t}$) at the highest calibrator ($10^{6}$ copies per reaction) is $16.4$ cycles. The instrument’s fluorescence threshold is fixed across runs, and reliable detection is defined as crossing threshold by $38.0$ cycles.\n\nStarting from the definition of polymerase chain reaction amplification, where the number of amplicon molecules after $t$ cycles is $N(t) = N_{0} (1+E)^{t}$ with $E$ the per-cycle efficiency, and using the fact that cycle threshold $C_{t}$ corresponds to reaching a fixed amplicon count $N_{\\mathrm{th}}$, derive, from first principles, the minimum initial template count $N_{0,\\mathrm{LOD}}$ (the Limit of Detection (LOD)) required to reach $N_{\\mathrm{th}}$ by $38.0$ cycles. Compute the numerical value of $N_{0,\\mathrm{LOD}}$ from the given parameters and express the final answer in copies per reaction. Round your answer to three significant figures.", "solution": "The fundamental base for quantification in Reverse Transcription Quantitative Polymerase Chain Reaction (RT-qPCR) is the exponential amplification model per cycle. If the initial number of target molecules is $N_{0}$ and the per-cycle efficiency is $E$, then after $t$ cycles the number of amplicon molecules is\n$$\nN(t) = N_{0} (1+E)^{t}.\n$$\nThe cycle threshold $C_{t}$ is defined as the cycle at which the amplicon quantity first reaches a fixed fluorescence threshold $N_{\\mathrm{th}}$. Therefore,\n$$\nN_{\\mathrm{th}} = N_{0} (1+E)^{C_{t}}.\n$$\nSolving for $C_{t}$ yields\n$$\nC_{t} = \\frac{\\ln\\!\\big(N_{\\mathrm{th}}/N_{0}\\big)}{\\ln(1+E)} = -\\frac{\\ln(N_{0})}{\\ln(1+E)} + \\frac{\\ln(N_{\\mathrm{th}})}{\\ln(1+E)}.\n$$\nConverting to base-$10$ logarithms,\n$$\nC_{t} = -\\frac{\\log_{10}(N_{0})}{\\log_{10}(1+E)} + \\frac{\\log_{10}(N_{\\mathrm{th}})}{\\log_{10}(1+E)}.\n$$\nThis linear relationship in $\\log_{10}(N_{0})$ has slope\n$$\nm = -\\frac{1}{\\log_{10}(1+E)}\n$$\nand intercept\n$$\nb = \\frac{\\log_{10}(N_{\\mathrm{th}})}{\\log_{10}(1+E)}.\n$$\nThese are well-tested consequences of the PCR exponential model and the definition of $C_{t}$.\n\nWe are given the per-cycle efficiency $E = 0.90$, hence $(1+E) = 1.90$. The fixed fluorescence threshold $N_{\\mathrm{th}}$ can be determined from any calibrator; using the highest calibrator with $N_{0,\\mathrm{high}} = 10^{6}$ copies per reaction and $C_{t,\\mathrm{high}} = 16.4$ cycles, we have\n$$\nN_{\\mathrm{th}} = N_{0,\\mathrm{high}} (1+E)^{C_{t,\\mathrm{high}}} = 10^{6} \\times 1.90^{16.4}.\n$$\nThe Limit of Detection (LOD) is defined here as the minimum initial template count $N_{0,\\mathrm{LOD}}$ that reaches the same threshold $N_{\\mathrm{th}}$ by the latest reliable detection cycle, $C_{t,\\mathrm{max}} = 38.0$. Therefore,\n$$\nN_{\\mathrm{th}} = N_{0,\\mathrm{LOD}} (1+E)^{C_{t,\\mathrm{max}}} \\quad \\Rightarrow \\quad N_{0,\\mathrm{LOD}} = \\frac{N_{\\mathrm{th}}}{(1+E)^{C_{t,\\mathrm{max}}}}.\n$$\nSubstituting $N_{\\mathrm{th}}$ from the calibrator,\n$$\nN_{0,\\mathrm{LOD}} = \\frac{10^{6} \\times 1.90^{16.4}}{1.90^{38.0}} = 10^{6} \\times 1.90^{16.4 - 38.0} = 10^{6} \\times 1.90^{-21.6}.\n$$\nTo compute this numerically, it is convenient to use logarithms:\n$$\n1.90^{-21.6} = 10^{-21.6 \\log_{10}(1.90)}.\n$$\nWe evaluate $\\log_{10}(1.90)$ and the product:\n$$\n\\log_{10}(1.90) \\approx 0.278753600952, \\quad 21.6 \\times 0.278753600952 \\approx 6.0210777805632.\n$$\nThus,\n$$\n1.90^{-21.6} = 10^{-6.0210777805632}.\n$$\nMultiplying by $10^{6}$,\n$$\nN_{0,\\mathrm{LOD}} = 10^{6} \\times 10^{-6.0210777805632} = 10^{-0.0210777805632}.\n$$\nFinally, compute $10^{-0.0210777805632}$ numerically. Using $\\ln(10) \\approx 2.302585093$,\n$$\n10^{-0.0210777805632} = \\exp\\!\\big(-0.0210777805632 \\times \\ln(10)\\big) \\approx \\exp(-0.048533376) \\approx 0.9526.\n$$\nRounded to three significant figures and expressed in copies per reaction, the Limit of Detection is $0.953$ copies per reaction.\n\nIt is noteworthy that the result is near one copy per reaction, reflecting consistency among the given slope $-3.6$, efficiency $0.90$, and the $6$-log dynamic range. The algebraic cancellation of $N_{\\mathrm{th}}$ via the calibrator substitution ensures the calculation is anchored to the fixed fluorescence threshold assumption and the exponential amplification model, satisfying the requirement to derive the LOD from first principles.", "answer": "$$\\boxed{0.953}$$", "id": "5099375"}, {"introduction": "Next-Generation Sequencing (NGS) has revolutionized the discovery of chromosomal translocations, but interpreting the data requires sophisticated quantitative reasoning. The observed variant allele fraction (VAF) of a fusion is not a simple readout of its prevalence, but is distorted by tumor purity and copy number alterations. This problem guides you through the process of building and applying a mathematical model to understand how these biological variables impact the expected VAF, a vital skill for accurately interpreting NGS data in a clinical or research setting [@problem_id:5099422].", "problem": "A clinical laboratory is validating a Next-Generation Sequencing (NGS) assay for detecting chromosomal translocations at deoxyribonucleic acid (DNA) breakpoints. In a tumor sample with tumor purity $p$ (the fraction of nucleated cells that are neoplastic), the breakpoints are assayed by counting junction-supporting molecules ($n_{\\text{junction}}$; split reads or read pairs whose alignment spans the fusion junction) and reference molecules ($n_{\\text{reference}}$; reads or read pairs spanning the corresponding wild-type locus without the junction). Variant allele fraction (VAF) for a fusion breakpoint is operationally defined for this assay as the fraction of molecules among those mapping across the breakpoint locus that carry the junction. The laboratory also tracks the tumor’s locus-specific total copy number in tumor cells, $C_{\\text{tumor}}$, and the number of those copies that carry the junction, $c_{\\text{var}}$. Normal (non-neoplastic) cells are assumed diploid, with total copy number $C_{\\text{normal}}=2$ and $c_{\\text{var}}=0$. Sequencing reads are assumed to sample molecules at random without allelic bias.\n\nConsider a case with observed counts $n_{\\text{junction}} = 80$ and $n_{\\text{reference}} = 220$ at a single breakpoint, for a total of $n = 300$ molecules. Orthogonal profiling estimates tumor purity $p = 0.6$. Copy-number profiling at the breakpoint locus in tumor cells indicates $C_{\\text{tumor}} = 3$, and structural variant phasing indicates $c_{\\text{var}} = 1$ (that is, one of the three tumor copies carries the fusion junction, two copies are unfused).\n\nWhich of the following statements are correct? Select all that apply.\n\nA. For a fusion breakpoint in DNA sequencing, $VAF$ is given by $VAF = \\dfrac{n_{\\text{junction}}}{n_{\\text{junction}} + n_{\\text{reference}}}$; under the random sampling model with tumor purity $p$, tumor total copy number $C_{\\text{tumor}}$, and junction-bearing copies $c_{\\text{var}}$, the expected $VAF$ equals $\\dfrac{p \\, c_{\\text{var}}}{p \\, C_{\\text{tumor}} + (1-p)\\cdot C_{\\text{normal}}}$.\n\nB. For a clonal heterozygous breakpoint present on exactly one of two tumor alleles in a diploid tumor ($C_{\\text{tumor}} = 2$, $c_{\\text{var}} = 1$), the expected $VAF$ simplifies to $VAF = \\dfrac{p}{2}$.\n\nC. With $p = 0.6$, $C_{\\text{tumor}} = 3$, $c_{\\text{var}} = 1$, the observed $VAF = \\dfrac{80}{300}$ is statistically inconsistent at significance level $\\alpha = 0.05$ with the expected model under binomial sampling.\n\nD. Holding $C_{\\text{tumor}}$ and $c_{\\text{var}}$ fixed, the expected $VAF$ increases monotonically as tumor purity $p$ increases.\n\nE. Copy-number gain of the fused allele (increasing $c_{\\text{var}}$ while holding $C_{\\text{tumor}}$ fixed) inflates the expected $VAF$, whereas copy-number gain of the unfused allele (increasing $C_{\\text{tumor}}$ while holding $c_{\\text{var}}$ fixed) depresses the expected $VAF$, even if the fusion is clonal.", "solution": "The problem statement is first validated for scientific soundness, clarity, and completeness.\n\n### Step 1: Extract Givens\n-   **Variables and Definitions:**\n    -   $p$: tumor purity, the fraction of neoplastic cells.\n    -   $n_{\\text{junction}}$: observed count of junction-supporting molecules.\n    -   $n_{\\text{reference}}$: observed count of reference (wild-type) molecules.\n    -   Variant allele fraction (VAF): Operationally defined as the fraction of molecules among those mapping across the breakpoint locus that carry the junction.\n    -   $C_{\\text{tumor}}$: locus-specific total copy number in tumor cells.\n    -   $c_{\\text{var}}$: number of tumor cell copies that carry the junction.\n    -   $C_{\\text{normal}}$: total copy number in normal (non-neoplastic) cells.\n    -   $c_{\\text{var}}$ in normal cells is $0$.\n-   **Constants and Conditions:**\n    -   $C_{\\text{normal}} = 2$.\n    -   Sequencing reads are assumed to sample molecules at random without allelic bias.\n-   **Specific Data for a Case:**\n    -   $n_{\\text{junction}} = 80$.\n    -   $n_{\\text{reference}} = 220$.\n    -   $p = 0.6$.\n    -   $C_{\\text{tumor}} = 3$.\n    -   $c_{\\text{var}} = 1$.\n\n### Step 2: Validate Using Extracted Givens\n-   **Scientific Grounding:** The problem describes a standard and widely accepted model in computational cancer genomics for relating the observed variant allele fraction of a somatic mutation to tumor purity and copy number aberrations. The concepts of tumor purity, copy number, junction reads for structural variants, and binomial sampling of sequencing reads are all fundamental to the field of molecular diagnostics and bioinformatics. The model is scientifically sound and realistic.\n-   **Well-Posedness:** All terms are explicitly defined. The provided information is self-contained and sufficient to evaluate each of the statements in the options. The task is to assess the correctness of statements based on the provided model and data, which is a well-defined objective.\n-   **Objectivity:** The problem is stated using precise, objective, and quantitative language. There are no subjective or ambiguous terms.\n-   **Conclusion:** The problem statement is valid as it is scientifically grounded, well-posed, objective, and free from any of the specified flaws.\n\n### Derivation and Option Analysis\nThe problem requires evaluating several statements about a model for the Variant Allele Fraction (VAF) of a chromosomal translocation. First, we establish the theoretical model for the expected VAF, $E[VAF]$.\n\nThe VAF represents the fraction of DNA molecules at a specific locus that carry the variant (the fusion junction). The total pool of DNA molecules is a mixture from tumor cells (fraction $p$) and normal cells (fraction $1-p$). Assuming the number of reads is proportional to the number of DNA copies:\n-   The contribution of junction-bearing copies comes solely from tumor cells. The relative abundance is proportional to (fraction of tumor cells) $\\times$ (number of junction copies per tumor cell) = $p \\cdot c_{\\text{var}}$.\n-   The total number of copies at the locus comes from both cell types. The relative abundance is proportional to (fraction of tumor cells) $\\times$ (total copies per tumor cell) + (fraction of normal cells) $\\times$ (total copies per normal cell) = $p \\cdot C_{\\text{tumor}} + (1-p) \\cdot C_{\\text{normal}}$.\n\nThus, the expected VAF is the ratio of these quantities:\n$$E[VAF] = \\dfrac{p \\, c_{\\text{var}}}{p \\, C_{\\text{tumor}} + (1-p)C_{\\text{normal}}}$$\n\nWith this model, we can evaluate each option.\n\n**A. For a fusion breakpoint in DNA sequencing, $VAF$ is given by $VAF = \\dfrac{n_{\\text{junction}}}{n_{\\text{junction}} + n_{\\text{reference}}}$; under the random sampling model with tumor purity $p$, tumor total copy number $C_{\\text{tumor}}$, and junction-bearing copies $c_{\\text{var}}$, the expected $VAF$ equals $\\dfrac{p \\, c_{\\text{var}}}{p \\, C_{\\text{tumor}} + (1-p)\\cdot C_{\\text{normal}}}$.**\n\nThe first part of the statement, $VAF = \\dfrac{n_{\\text{junction}}}{n_{\\text{junction}} + n_{\\text{reference}}}$, is the empirical VAF calculated from observed counts. The problem states that VAF is \"operationally defined for this assay as the fraction of molecules among those mapping across the breakpoint locus that carry the junction.\" This matches the formula.\nThe second part of the statement gives the formula for the expected VAF. As derived above, this formula correctly models the VAF based on the biological parameters.\nTherefore, the entire statement is correct.\n\nVerdict: **Correct**.\n\n**B. For a clonal heterozygous breakpoint present on exactly one of two tumor alleles in a diploid tumor ($C_{\\text{tumor}} = 2$, $c_{\\text{var}} = 1$), the expected $VAF$ simplifies to $VAF = \\dfrac{p}{2}$.**\n\nThis statement describes a specific scenario. We use the general formula for $E[VAF]$ with the given parameters: $C_{\\text{tumor}} = 2$, $c_{\\text{var}} = 1$, and the standard $C_{\\text{normal}} = 2$.\n$$E[VAF] = \\dfrac{p \\cdot 1}{p \\cdot 2 + (1-p) \\cdot 2} = \\dfrac{p}{2p + 2 - 2p} = \\dfrac{p}{2}$$\nThe derivation is correct. Although the statement uses \"VAF\" instead of \"$E[VAF]$\", the context \"the expected VAF simplifies to\" makes the meaning clear.\n\nVerdict: **Correct**.\n\n**C. With $p = 0.6$, $C_{\\text{tumor}} = 3$, $c_{\\text{var}} = 1$, the observed $VAF = \\dfrac{80}{300}$ is statistically inconsistent at significance level $\\alpha = 0.05$ with the expected model under binomial sampling.**\n\nFirst, we calculate the observed VAF and the expected VAF from the given data.\nObserved VAF: $VAF_{obs} = \\dfrac{n_{\\text{junction}}}{n_{\\text{junction}} + n_{\\text{reference}}} = \\dfrac{80}{80 + 220} = \\dfrac{80}{300} = \\dfrac{4}{15} \\approx 0.2667$.\nExpected VAF: $E[VAF] = P_{exp} = \\dfrac{p \\, c_{\\text{var}}}{p \\, C_{\\text{tumor}} + (1-p)C_{\\text{normal}}} = \\dfrac{0.6 \\cdot 1}{0.6 \\cdot 3 + (1-0.6) \\cdot 2} = \\dfrac{0.6}{1.8 + 0.4 \\cdot 2} = \\dfrac{0.6}{1.8 + 0.8} = \\dfrac{0.6}{2.6} = \\dfrac{6}{26} = \\dfrac{3}{13} \\approx 0.2308$.\n\nWe test the null hypothesis $H_0: P = P_{exp} = 3/13$, where $P$ is the true VAF. The number of junction reads $n_{\\text{junction}}$ is modeled as a binomial random variable $X \\sim B(n, P)$ with $n = 300$ trials and observed successes $k = 80$.\nSince $n$ is large, we can use the normal approximation to the binomial distribution. The test statistic $Z$ is:\n$$Z = \\dfrac{k - nP_{exp}}{\\sqrt{nP_{exp}(1-P_{exp})}}$$\nExpected number of junction reads: $n P_{exp} = 300 \\cdot (3/13) \\approx 69.23$.\n$$Z = \\dfrac{80 - 69.23}{\\sqrt{300 \\cdot (3/13) \\cdot (10/13)}} = \\dfrac{10.77}{\\sqrt{69.23 \\cdot (10/13)}} = \\dfrac{10.77}{\\sqrt{53.25}} \\approx \\dfrac{10.77}{7.297} \\approx 1.476$$\nFor a two-tailed test at significance level $\\alpha = 0.05$, the critical values are $Z_{crit} = \\pm 1.96$. Since $|Z| \\approx 1.476 < 1.96$, we fail to reject the null hypothesis. The observed VAF is statistically *consistent* with the expected model. The statement claims it is inconsistent.\n\nVerdict: **Incorrect**.\n\n**D. Holding $C_{\\text{tumor}}$ and $c_{\\text{var}}$ fixed, the expected $VAF$ increases monotonically as tumor purity $p$ increases.**\n\nWe analyze the behavior of $E[VAF]$ as a function of $p$, for $p \\in [0, 1]$.\nLet $V(p) = \\dfrac{p \\, c_{\\text{var}}}{p \\, C_{\\text{tumor}} + (1-p)C_{\\text{normal}}} = \\dfrac{p \\, c_{\\text{var}}}{p(C_{\\text{tumor}} - C_{\\text{normal}}) + C_{\\text{normal}}}$.\nTo determine monotonicity, we find the derivative of $V(p)$ with respect to $p$. Using the quotient rule $\\left(\\frac{u}{v}\\right)' = \\frac{u'v - uv'}{v^2}$:\n$$V'(p) = \\dfrac{c_{\\text{var}} \\left[ p(C_{\\text{tumor}} - C_{\\text{normal}}) + C_{\\text{normal}} \\right] - p \\, c_{\\text{var}} \\left[ C_{\\text{tumor}} - C_{\\text{normal}} \\right]}{\\left(p(C_{\\text{tumor}} - C_{\\text{normal}}) + C_{\\text{normal}}\\right)^2}$$\n$$V'(p) = \\dfrac{p c_{\\text{var}}(C_{\\text{tumor}} - C_{\\text{normal}}) + c_{\\text{var}}C_{\\text{normal}} - p c_{\\text{var}}(C_{\\text{tumor}} - C_{\\text{normal}})}{\\left( \\text{denominator} \\right)^2}$$\n$$V'(p) = \\dfrac{c_{\\text{var}} C_{\\text{normal}}}{\\left(p C_{\\text{tumor}} + (1-p)C_{\\text{normal}}\\right)^2}$$\nThe denominator is the square of the average copy number, which is always positive. The numerator contains $c_{\\text{var}}$ (number of junction copies, $c_{\\text{var}} \\ge 1$ for a detected fusion) and $C_{\\text{normal}}=2$. Both are positive. Thus, $V'(p) > 0$ for all $p$ in its domain. This proves that the expected VAF is a strictly monotonically increasing function of tumor purity $p$.\n\nVerdict: **Correct**.\n\n**E. Copy-number gain of the fused allele (increasing $c_{\\text{var}}$ while holding $C_{\\text{tumor}}$ fixed) inflates the expected $VAF$, whereas copy-number gain of the unfused allele (increasing $C_{\\text{tumor}}$ while holding $c_{\\text{var}}$ fixed) depresses the expected $VAF$, even if the fusion is clonal.**\n\nWe analyze the partial derivatives of the expected VAF function $V(C_{\\text{tumor}}, c_{\\text{var}}) = \\dfrac{p \\, c_{\\text{var}}}{p \\, C_{\\text{tumor}} + (1-p)C_{\\text{normal}}}$.\n1.  Effect of increasing $c_{\\text{var}}$: The numerator $p \\, c_{\\text{var}}$ is directly proportional to $c_{\\text{var}}$, while the denominator is held constant. Therefore, as $c_{\\text{var}}$ increases, the value of the fraction increases (\"inflates\"). This is true as long as $p>0$.\n2.  Effect of increasing $C_{\\text{tumor}}$: The numerator $p \\, c_{\\text{var}}$ is held constant. The denominator $p \\, C_{\\text{tumor}} + (1-p)C_{\\text{normal}}$ increases linearly with $C_{\\text{tumor}}$ (since $p > 0$). When the numerator of a positive fraction is constant and the denominator increases, the fraction's value decreases (\"depresses\"). This corresponds to adding more unfused (wild-type) copies in the tumor, which dilutes the variant signal.\n\nBoth claims in the statement are correct descriptions of the model's behavior. The clonality reference simply confirms the model's applicability.\n\nVerdict: **Correct**.\n\nFinal tally of correct options: A, B, D, E.", "answer": "$$\\boxed{ABDE}$$", "id": "5099422"}]}